Login to Your Account

InterMune Begins Phase III Trial Of Once-Daily Infergen

By Kim Coghill

Wednesday, June 16, 2004
InterMune Inc. started a Phase III trial to evaluate the once-daily use of Infergen in combination with ribavirin for patients chronically infected with hepatitis C virus who have failed to respond to a previous course of therapy with pegylated interferon alfa-2 plus ribavirin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription